Praxis Impact Large Cap Value ETF
PRXV - ETF AI Analysis
Top Page
Praxis Impact Large Cap Value ETF (PRXV)
PRXV, the Praxis Impact Large Cap Value ETF, earns a solid overall rating thanks to several high-quality blue-chip holdings like Micron, Merck, Johnson & Johnson, Walmart, and Cisco, which combine strong financial performance with growth drivers in areas such as AI, healthcare, and e-commerce. The fund is slightly held back by names like AbbVie and Procter & Gamble, where valuation and leverage concerns, along with some bearish technical signals, introduce more uncertainty. The main risk factor is that many core holdings face valuation and debt-related pressures, which could limit future upside if market conditions weaken.
PRXV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 97.40M
- Region
- North America
- Expense Ratio
- 0.36%
- Beta
- 0.53
- Issuer
- Praxis
- Inception Date
- Apr 07, 2025
- Dividend Yield
- 1.46%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
PRXV Summary
Praxis Impact Large Cap Value ETF (PRXV) is a U.S. stock fund that focuses on large, established companies that appear undervalued and also meet strict environmental, social, and governance (ESG) standards. It doesn’t track a traditional index, but follows a value and impact theme, aiming to combine long-term growth with positive social outcomes. The fund holds well-known names like JPMorgan Chase, Johnson & Johnson, Walmart, and Coca-Cola, giving investors broad exposure to financials, health care, technology, and more. A key risk is that value stocks and the overall stock market can go up and down, so your investment may lose value.
How much will it cost me?
This ETF has an expense ratio of 0.36%, which means you’ll pay about $3.60 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because this fund is actively managed and also applies ESG screens, which generally cost more to run.
What would affect this ETF?
PRXV could benefit if the U.S. economy stays resilient, interest rates stabilize or fall (supporting its large financial holdings), and demand grows for healthcare, technology, and everyday consumer products, especially as more investors favor socially responsible companies. On the downside, higher interest rates, U.S.-focused economic slowdowns, pressure on banks or energy companies, or changes in ESG regulations and sentiment could weigh on the fund’s mainly U.S. large-cap value holdings.
PRXV Top 10 Holdings
PRXV leans heavily into U.S. financials and health care, with JPMorgan acting as a steady but not spectacular anchor while Micron’s recent pullback has slightly weighed on returns despite its strong year-to-date run. On the defensive side, Walmart, Coca-Cola, and Procter & Gamble are quietly doing the heavy lifting, with rising, resilient performance that smooths out volatility. AbbVie and Merck add more health care punch, mostly trending higher. Overall, the fund is a U.S.-centric, large-cap value play with a tilt toward banks, drugmakers, and a dash of tech cyclicality.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| JPMorgan Chase | 3.48% | $3.41M | $919.35B | 11.86% | 72Outperform | |
| Micron | 3.43% | $3.36M | $880.60B | 228.47% | 79Outperform | |
| Johnson & Johnson | 2.89% | $2.83M | $687.89B | 46.35% | 78Outperform | |
| Walmart | 2.22% | $2.18M | $1.02T | 24.92% | 78Outperform | |
| AbbVie | 2.11% | $2.07M | $521.50B | 27.01% | 66Neutral | |
| Coca-Cola | 1.84% | $1.80M | $426.96B | 39.65% | 75Outperform | |
| Procter & Gamble | 1.82% | $1.78M | $393.56B | 14.76% | 69Neutral | |
| Cisco Systems | 1.43% | $1.40M | $376.53B | 23.60% | 77Outperform | |
| Merck & Company | 1.41% | $1.38M | $364.26B | 59.00% | 80Outperform | |
| Home Depot | 1.41% | $1.38M | $347.88B | -5.27% | 66Neutral |
PRXV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRXV, the sentiment is Positive. The current price of 36.83 is above the 20-day moving average (MA) of 36.37, above the 50-day MA of 35.75, and above the 200-day MA of 33.97, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 59.11 is Neutral, neither overbought nor oversold. The STOCH value of 79.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRXV.
PRXV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $36.83 | $40.00(8.61% Upside) | $97.40M | 0.36% | 72Outperform | |
| $141.05 | $167.40(18.68% Upside) | $93.69M | 0.75% | 74Outperform | |
| $26.14 | $29.70(13.63% Upside) | $74.39M | 0.38% | 72Outperform | |
| $32.15 | $35.69(11.00% Upside) | $73.18M | 0.60% | 68Neutral | |
| $14.29 | $16.27(13.87% Upside) | $69.44M | 0.55% | 73Outperform | |
| $32.21 | $34.70(7.74% Upside) | $48.85M | 0.58% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRXV | Praxis Impact Large Cap Value ETF | 36.83 | 7.96 | 27.58% | |
| MAVF | Matrix Advisors Value ETF | 141.05 | 25.95 | 22.55% | |
| NSIV | North Square Disciplined Value ETF | 26.14 | 1.05 | 4.20% | |
| PZLV | Pzena U.S. Large Cap Value ETF | 32.15 | 7.05 | 28.09% | |
| DHLX | Diamond Hill Large Cap Concentrated ETF | 14.29 | 1.76 | 14.07% | |
| MDLV | Morgan Dempsey Large Cap Value ETF | 32.21 | 5.04 | 18.53% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
